Bionomics

Candlestick Daily volume index Bar reversal Edit

Backtest results

Position Trades Duration Win rate Win/loss Avg win Avg loss Return
Long 10 4.5 20% 25% 1.6% -0.8% -3.4%
Short 5 4.2 40% 67% 1.9% -3.2% -5.9%

What indicators would you like to backtest?

Trading Performance

Simple Moving Average

Score

-0.1

Position Trades Duration Win Rate Win/Loss Avg Win Avg Loss Return
LONG 51 6.5 0.14% 0.15% 17.1% -3.7% -50.8%
SHORT 51 9.8 0.25% 0.30% 22.1% -4.2% 108.1%

Summary

Technical Analysis

Bionomics (BNO.AX)


Indicator:

SIMPLE MOVING AVERAGE


Last Signal:

BEARISH


Trading: SELL @ $0.061
Signal Strength: STRONG
Recommendation:

Indicator can be used in isolation or in additional to another technical indicator to confirmation for trading entry. This indicator has the ability to highlight trends across numerous timeframes. This indicator has the ability to smooth historical results to illustrate trend initiation and status. Although this is a simple trend following indicator & can provide good results when coupled with the right indicator. Note, this indicator does not work well in ranging markets producing unwanted whipsaws and false signals.


Bionomics (ASX:BNO) currently has a confirmed downtrend. This means the SMA 15 day average has moved below the closing price confirming the short term trend following indicator. Currently, the return on SMA15 is -3.2%.



A simple moving average is formed by computing the average price of a security over a specific number of periods. Most moving averages are based on closing prices.

Calculation: Simple Moving Average:
1) SMA: n period sum / n;


PROFILE: Bionomics (BNO.AX)


Stock Exchange: ASX
Company: Bionomics
Ticker Codes: | BNO.AX | ASX:BNO |

About Bionomics (ASX:BNO):

Bionomics Limited, a clinical-stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancer in Australia, France, and the United States. It operates through Drug Discovery and Development, and Contract Services segments. The company's product pipeline includes BNC210, a novel and proprietary negative allosteric modulator, which is in Phase II clinical trial for the treatment of generalized anxiety disorder, as well as is in the initiation of a Phase II clinical trial in patients with post-traumatic stress disorder; BNC375, a small molecule therapeutics for the treatment of cognitive impairment in Alzheimer's disease; BNC101, a monoclonal antibody that targets cancer stem cells; and BNC105, a vascular disrupting agent for the treatment of cancer, as well as disrupts the blood vessels that nourish tumors in cancer treatment. It also offers contract research services. The company has partnerships with Merck & Co., Inc.; Cancer Therapeutics Cooperative Research Centre; Genmab A/S; Laboratory Corporation of America (LabCorp); Athena Diagnostics; and Genetic Technologies Limited. Bionomics Limited was founded in 1998 and is based in Thebarton, Australia.

Top 10:

Simple Moving Average

Download
Company Close Change(%) Volume Value Signal
DCN Dacian Gold 0.55 23.6 6,024,943 -44.4 BEARISH
GTN GTN Resources 1.1 10 161,378 -1.2 BEARISH
LNG Liquefied Natural Gas 0.29 9.6 1,664,251 -0.5 BEARISH
TZN Terramin Australia 0.08 8.7 388,211 -2.1 BEARISH
VTG Vita 1.25 5.9 714,854 -16.8 BEARISH
SMX Sms Management & Technology 0.39 5.4 102,965 -0.6 BEARISH
KMD Kathmandu 2.06 4.3 154,871 -2 BEARISH
FBR Fastbrick Robotics 0.08 4.2 978,830 -2.6 BEARISH
BBN Baby Bunting 2.18 3.8 510,542 -3.6 BEARISH
SXY Senex Energy 0.29 3.6 10,559,722 -3.6 BEARISH